Replies to post #93596 on Biotech Values

[DewDiligence]

ACHN:

…the president states in his introductory remarks about ACH-1625 that ACHN has a "hold up in some clinical development here" among a few other initial remarks that are otherwise clearly positive... So, I'm not sure I understand the aforementioned statement as it was clearly out of context from the rest of the discussion regarding 1625. It was probably just a misstatement or I'm reading into it too much.

Nothing untoward—he simply meant that there’s work to do in the clinic before one can proclaim the program a success.

[turtlepower]

ACHN -

According to the president, at the 5 day mark, 1625 produced the "single deepest viral load reduction that anyone has been able to produce.

From the presentation slides it appears that the lower dose (500 mg)produces better viral reduction than the 600 mg. Does this make sense? Do you also happen to have an idea of how the additional dosing cohorts would be different?

As a comparison, from what I can find, Telapravir monotherapy produced a 5 log reduction but at 14 days of dosing, in a p1 trial.